Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis

Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis

Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade of CD25 inhibits effector T cell activation, regulatory T cell expansion and survival, and activation-induced T-cell apoptosis. Because CD25...

Full description

Bibliographic Details
Main Authors: Stanley L. Cohan, Elisabeth B. Lucassen, Meghan C. Romba, Stefanie N. Linch
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:Biomedicines
Subjects:
daclizumab
relapsing multiple sclerosis
CD25
innate immune system
interleukin-2
drug reaction with eosinophilia systemic symptoms
DRESS
autoimmunity
Online Access:http://www.mdpi.com/2227-9059/7/1/18

Internet

http://www.mdpi.com/2227-9059/7/1/18

Similar Items